Back

The BET protein inhibitor Apabetalone rescues cardiometabolic heart failure with preserved ejection fraction by suppressing myocardial and systemic inflammation: a study in mice and humans

29 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Genetic and epigenetic regulation of cardiovascular disease: mechanisms and therapeutic opportunities Heart Failure ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Era Gorica

Center for Translational and Experimental Cardiology (CTEC), Zurich (Switzerland)

6 More presentations in this session

Presentation thumbnail
N6-methyladenosine regulator Rbm15b protects against adverse cardiac remodeling under pressure overload through modulating RNA methylation
Doctor Y. Higashikuni (Tochigi, JP)
Abstract Slides Video
Presentation thumbnail
Modeling cardioinflammatory TET2 CHIP in engineered cardiac ventricular tissue reveals therapeutics for disease resolution
Doctor Y. Wang (Frankfurt, DE)
Abstract Slides Video
Presentation thumbnail
Epigenetic editing of chromatin readers rescues doxorubicin-induced endothelial senescence and vascular dysfunction
Doctor S. Mohammed (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Longer leucocyte telomere length protects from adverse cardiovascular effects of prolonged air pollution exposure
Doctor M. Sagris (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Unraveling the molecular mechanisms underlying the coronary artery disease risk gene REST
Doctor T. Dang (Munich, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Genetic and epigenetic regulation of cardiovascular disease: mechanisms and therapeutic opportunities

The Event

Event poster

ESC Congress 2025

29 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
The BET inhibitor Apabetalone protects against heart failure with preserved ejection fraction by suppressing myocardial inflammation
thumbnail
Congress Presentation
Epigenetic BET inhibitor apabetalone counters inflammatory and fibrotic processes in activated cardiac fibroblasts providing insight into reduced hospitalizations for heart failure in BETonMACE trial
thumbnail
Congress Presentation
Emerging therapies to prevent perivascular fat dysfunction in cardiometabolic heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources